Get the Stockscreener App
3.935
0.00%
0.015
Ataibeckley Inc stock is traded at $3.935, with a volume of 1.12M.
It is up +0.00% in the last 24 hours and down -2.37% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$3.92
Open:
$3.98
24h Volume:
1.12M
Relative Volume:
0.20
Market Cap:
$1.45B
Revenue:
$4.09M
Net Income/Loss:
$-660.15M
P/E Ratio:
-1.7069
EPS:
-2.3053
Net Cash Flow:
$-117.10M
1W Performance:
+2.89%
1M Performance:
-2.37%
6M Performance:
-5.31%
1Y Performance:
+85.78%
1-Day Range:
$3.8902
$4.0665
1-Week Range:
$3.6701
$4.0665
52-Week Range:
$2.00
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.925 | 1.44B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
450.01 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.36 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.59 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.43 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
158.50 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
ATAI: Advancing late-stage psychedelics for depression with key data readouts and strong financial runway - TradingView
ATAI: Advancing late-stage psychedelics for mental health, with key phase III and II-B trials underway - TradingView
Is AtaiBeckley Inc. (ATAI) the Hidden Penny Stock to Invest In? - Yahoo Finance
AtaiBeckley Inc. (ATAI) Holds Above Key Support, Posts Modest GainTrend Continuation Trade - newsline.com
ATAIBECKLEY INC. Files Form 8-K with SEC: Company Details, Stock Information, and NASDAQ Listing - Minichart
H.C. Wainwright reiterates Buy on Atai stock, $25 target By Investing.com - Investing.com Australia
AtaiBeckley Inc. (ATAI) awards 121,968 stock options to director - Stock Titan
AtaiBeckley Inc. (ATAI) director granted 121,968 stock options at $4.50 - Stock Titan
AtaiBeckley (ATAI) grants director 121,968 stock options at $4.50 - Stock Titan
AtaiBeckley (NASDAQ: ATAI) shareholders back board slate and Deloitte as 2026 auditor - Stock Titan
H.C. Wainwright reiterates Buy on Atai stock, $25 target - Investing.com UK
Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder Value - Yahoo Finance
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Declines Amid Market VolatilityEarnings Quality Score - newsline.com
AtaiBeckley (ATAI) Among the Best Penny Stocks with Huge Upside Potential - Insider Monkey
AtaiBeckley (ATAI) Drops Over 12%: Testing Key Support at $3.75Value Stock Ideas - newsline.com
5 Best Penny Stocks with Huge Upside Potential - Insider Monkey
Small cap wrap: Gunnison Copper, Trillion Energy, AtaiBeckley… - Proactive financial news
AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy’ rating - Yahoo! Finance Canada
Is AtaiBeckley’s BPL-003 Phase 3 Launch Altering The Investment Case For AtaiBeckley (ATAI)? - Yahoo Finance
Jefferies reiterates atai Life Sciences stock rating on pipeline progress - Investing.com
Assessing AtaiBeckley (ATAI) Valuation After Strong Returns And Elevated Price To Book Ratio - Yahoo Finance
Is AtaiBeckley (ATAI) Using BPL-003’s Phase 3 Launch to Redefine Its Risk‑Reward Profile? - simplywall.st
ATAI: BPL-003 enters phase III for depression, with top-line data expected in early 2029 - TradingView
ATAI: BPL-003 phase III for depression begins, with VLS-01 phase IIb results due Q4 2024 - TradingView
AtaiBeckley to discuss Phase 3 BPL-003 program at multiple June investor conferences - TradingView
AtaiBeckley (NASDAQ: ATAI) to present BPL-003 Phase 3 updates - Stock Titan
ATAI Q1 2026 Earnings: Narrower Than Expected Loss Drives Positive Surprise Despite Modest Stock Decline - newsline.com
AtaiBeckley Grant Program Links Mental Health Impact With Investor Considerations - Sahm
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Edges HigherEarnings Weakness Phase - thelegaladvocate.com
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations - Investing News Network
Small cap wrap: AtaiBeckley, Medicus Pharma, Bit Digital, American Resources, Nextech3D.ai… - Proactive financial news
AtaiBeckley launches mental health patient impact grant program - Proactive financial news
New $20,000 mental health grants for nonprofits now open for applications - Stock Titan
AtaiBeckley to present at multiple investor conferences in June 2026, highlighting its mental health drug pipeline. - Pluang
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 - Investing News Network
AtaiBeckley to participate in multiple June investor conferences - Proactive financial news
AtaiBeckley Inc. Cash Flow – HAM:B72 - TradingView
Total debt of AtaiBeckley Inc. – HAM:B72 - TradingView
AtaiBeckley Inc. Balance Sheet – HAM:B72 - TradingView
Return on assets % of AtaiBeckley Inc. – HAM:B72 - TradingView
AtaiBeckley Inc. Trade Ideas — HAM:B72 - TradingView
ATAI Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesInterim Report - newsline.com
ATAI Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesRevenue Beat Analysis - newsline.com
AtaiBeckley (ATAI) Reports Q1 Financial Results - Insider Monkey
AtaiBeckley Inc. (ATAI) Surges 5.87%: Testing Key Resistance LevelsDip Buy Trade - The Legal Advocate
10 Best Penny Stocks to Buy for Long Term - Insider Monkey
These stocks are today’s movers: Fermi, AST SpaceMobile, Intel, Marvell, USA Rare Earth, Ataibeckley, and more - MSN
AtaiBeckley Inc. (NASDAQ: ATAI): Advancing Psychedelic Mental Health Therapies with Clinical Momentum - Kalkine
How AtaiBeckley’s Wider Q1 Loss But Lower Per-Share Hit At AtaiBeckley (ATAI) Has Changed Its Investment Story - simplywall.st
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - marketscreener.com
A Look At AtaiBeckley (ATAI) Valuation As Share Price Momentum And DCF Signal Differ - Yahoo Finance
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):